SEC Filing Summary: Park Ha Biological Technology Co., Ltd.
Business Context and Reporting Period
This Form 6-K filing covers the month of March 2026 for Park Ha Biological Technology Co., Ltd., a foreign private issuer headquartered in Wuxi, China. The report addresses a specific regulatory matter regarding the Company's listing status on the Nasdaq Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of regulatory compliance and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the resolution of a listing deficiency. On March 6, 2026, the Company received confirmation from the Nasdaq Listing Qualifications Department that it regained compliance with the minimum bid price requirement of $1.00 per share. This compliance was achieved after the Class A ordinary shares closed at or above $1.00 for 10 consecutive business days between February 20 and March 5, 2026. The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks, contingencies, or unusual items were disclosed in this specific report.
Key Facts for Investor Verification
- The Company has successfully regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price.
- The compliance period was February 20 through March 5, 2026.
- The Nasdaq Listing Qualifications Department has officially closed the matter as of March 6, 2026.
- No financial performance data is included in this filing.